BG99593A - Приложение на диметилбензофурани като 5-нт долу 3 антагонисти - Google Patents

Приложение на диметилбензофурани като 5-нт долу 3 антагонисти

Info

Publication number
BG99593A
BG99593A BG99593A BG9959395A BG99593A BG 99593 A BG99593 A BG 99593A BG 99593 A BG99593 A BG 99593A BG 9959395 A BG9959395 A BG 9959395A BG 99593 A BG99593 A BG 99593A
Authority
BG
Bulgaria
Prior art keywords
hydrogen
formula
compounds
dtmethylbenzofurans
antagonists
Prior art date
Application number
BG99593A
Other languages
English (en)
Other versions
BG62489B1 (bg
Inventor
Daele Georges Van
Jean-Paul Bosmans
Laerhoven Willy Van
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of BG99593A publication Critical patent/BG99593A/bg
Publication of BG62489B1 publication Critical patent/BG62489B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Dental Preparations (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Съединенията се използват за лечение на свързани с 5-НТ3 нарушения чрез систематично подаване на ефективно количество от съединение с формула и на негови фармацевтично приемливисоли и стереохимични изомерни форми. Във формулатарадикалите R1 и R2 означават водород или R1 и R2 заедно образуват двувалентен радикал с формула -СН=СН-СН=СН- (а),-СН=С(Сl)-СН=СН- (b) или -СН=СН- С(Сl)=СН- (с), n има стойност 2, 3 или 4, R3 е водород или метокси, m има стойност 1 или 2, R4 е водород, амино или С1-3алкилкарбониламино и R5 е водород или халоген. Изобретението се отнася също до нови съединения и състави и до методи за получаване на нови и междинни съединения.
BG99593A 1992-11-20 1995-04-20 Приложение на диметилбензофурани като 5-нт3 антагонисти BG62489B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97901392A 1992-11-20 1992-11-20
PCT/EP1993/003206 WO1994012494A1 (en) 1992-11-20 1993-11-15 Use of dimethylbenzofurans and dimethylbenzopyrans as 5-ht3 antagonists

Publications (2)

Publication Number Publication Date
BG99593A true BG99593A (bg) 1995-12-29
BG62489B1 BG62489B1 (bg) 1999-12-30

Family

ID=25526607

Family Applications (1)

Application Number Title Priority Date Filing Date
BG99593A BG62489B1 (bg) 1992-11-20 1995-04-20 Приложение на диметилбензофурани като 5-нт3 антагонисти

Country Status (31)

Country Link
US (2) US5674868A (bg)
EP (1) EP0669919B1 (bg)
JP (1) JP2830952B2 (bg)
KR (1) KR0166661B1 (bg)
AT (1) ATE176232T1 (bg)
AU (1) AU680640B2 (bg)
BG (1) BG62489B1 (bg)
BR (1) BR9307477A (bg)
CA (1) CA2149044C (bg)
CZ (1) CZ287262B6 (bg)
DE (1) DE69323322T2 (bg)
DK (1) DK0669919T3 (bg)
ES (1) ES2129615T3 (bg)
FI (1) FI952458A7 (bg)
GR (1) GR3029831T3 (bg)
HU (2) HUT72740A (bg)
IL (3) IL107654A (bg)
LV (1) LV10956B (bg)
MX (1) MX9307257A (bg)
NO (2) NO307690B1 (bg)
NZ (1) NZ257854A (bg)
OA (1) OA10158A (bg)
PL (1) PL176051B1 (bg)
RO (1) RO115160B1 (bg)
RU (1) RU2116072C1 (bg)
SG (1) SG47488A1 (bg)
SK (1) SK282378B6 (bg)
TW (1) TW294595B (bg)
UA (1) UA49792C2 (bg)
WO (1) WO1994012494A1 (bg)
ZA (1) ZA938676B (bg)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
PT975327E (pt) 1997-04-18 2003-11-28 Janssen Pharmaceutica Nv Uso de antagonistas de 5ht3 para estimular a lavagem intestinal
CN1196681C (zh) * 1997-07-11 2005-04-13 詹森药业有限公司 (+)诺西沙必利用于制备5－ht3和5ht4 介导的疾病的药物中的用途
US6239122B1 (en) * 2000-01-05 2001-05-29 Joy Ann Steele Method of treatment of nausea, vomiting, and other disorders using estrogens
EP1646615B1 (en) * 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
BRPI0416206A (pt) 2003-11-20 2006-12-26 Janssen Pharmaceutica Nv 2-quinolinonas e 2-quinoxalinonas substituìdas por 6-alquenila e 6-fenilalquila como inibidores de polimerase de poli(adp-ribose)
CA2546002C (en) 2003-11-20 2012-09-18 Janssen Pharmaceutica N.V. 7-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
ATE540936T1 (de) * 2004-06-30 2012-01-15 Janssen Pharmaceutica Nv Substituierte 2-alkyl-chinazolinonderivate als parp-hemmer
SG154433A1 (en) 2004-06-30 2009-08-28 Janssen Pharmaceutica Nv Phthalazine derivatives as parp inhibitors
EA011552B1 (ru) 2004-06-30 2009-04-28 Янссен Фармацевтика Н.В. Производные хиназолиндиона в качестве ингибиторов parp
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
CN101981013B (zh) 2008-03-27 2013-05-29 詹森药业有限公司 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
ES2367760T3 (es) 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ZW12187A1 (en) * 1986-07-03 1989-02-01 Janssen Pharmaceutica Nv 4-(aroylamino)piperidinebutanamide derivatives
CA1317940C (en) * 1987-09-25 1993-05-18 Georges H. P. Van Daele Substituted n-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5374637A (en) * 1989-03-22 1994-12-20 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives
US4914207A (en) * 1989-05-09 1990-04-03 Pfizer Inc. Arylthiazolylimidazoles
GB9005014D0 (en) * 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives

Also Published As

Publication number Publication date
BR9307477A (pt) 1999-06-29
US5674868A (en) 1997-10-07
NO308530B1 (no) 2000-09-25
UA49792C2 (uk) 2002-10-15
KR0166661B1 (ko) 1999-01-15
PL176051B1 (pl) 1999-03-31
NO951980L (no) 1995-05-19
SG47488A1 (en) 1998-04-17
CZ287262B6 (en) 2000-10-11
ATE176232T1 (de) 1999-02-15
NO307690B1 (no) 2000-05-15
ES2129615T3 (es) 1999-06-16
IL107654A (en) 1998-01-04
EP0669919B1 (en) 1999-01-27
DK0669919T3 (da) 1999-09-13
LV10956A (lv) 1995-12-20
PL309045A1 (en) 1995-09-18
US5863923A (en) 1999-01-26
IL119273A0 (en) 1996-12-05
TW294595B (bg) 1997-01-01
SK282378B6 (sk) 2002-01-07
GR3029831T3 (en) 1999-06-30
CA2149044C (en) 2007-04-03
IL107654A0 (en) 1994-02-27
BG62489B1 (bg) 1999-12-30
CA2149044A1 (en) 1994-06-09
CZ125895A3 (en) 1995-10-18
JP2830952B2 (ja) 1998-12-02
AU680640B2 (en) 1997-08-07
FI952458L (fi) 1995-05-19
SK67595A3 (en) 1995-11-08
JPH08505840A (ja) 1996-06-25
RU95113434A (ru) 1997-03-10
FI952458A0 (fi) 1995-05-19
AU5465994A (en) 1994-06-22
IL119273A (en) 2000-07-16
DE69323322T2 (de) 1999-09-09
LV10956B (en) 1996-10-20
NO995762D0 (no) 1999-11-24
HU9501476D0 (en) 1995-07-28
HU211546A9 (en) 1995-12-28
EP0669919A1 (en) 1995-09-06
NO995762L (no) 1995-05-19
ZA938676B (en) 1995-05-19
NO951980D0 (no) 1995-05-19
OA10158A (en) 1996-12-18
HUT72740A (en) 1996-05-28
RU2116072C1 (ru) 1998-07-27
MX9307257A (es) 1994-05-31
WO1994012494A1 (en) 1994-06-09
NZ257854A (en) 1997-04-24
RO115160B1 (ro) 1999-11-30
FI952458A7 (fi) 1995-05-19
DE69323322D1 (de) 1999-03-11

Similar Documents

Publication Publication Date Title
BG99593A (bg) Приложение на диметилбензофурани като 5-нт долу 3 антагонисти
GB9524157D0 (en) Therapeutic agents
DE69633607D1 (de) Piperidinderivate mit tachykinin-antagonistischer wirkung
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
MY116542A (en) New inhibitors of platelet aggregation.
MX9504349A (es) Derivados de aroilpiperidina.
RU92004482A (ru) Производные изоиндола
NO955047L (no) Sekundære aminer som antidiabetiske og antifedme-midler
SE0104332D0 (sv) Therapeutic agents
EA200100710A1 (ru) 4-(аминометил)пиперидинбензамиды для лечения желудочно-кишечных расстройств
BG94282A (bg) 2,9-дизаместени-4н-пиридо/1,2,-а/пиримидин-4-они
PL322872A1 (en) Novel triazolones - inhibitors of b apolipoprotein synthesis
MD554G2 (ro) Derivaţi noi ai triazolpirimidinelor, antagonişti ai receptorilor angiotensinei II, procedee de preparare a lor, compoziţii farmaceutice care le conţin
LV11545A (lv) Pozitivas inotropas un lusitropas iedarbibas pirolohinolinona atvasinajumi
DK0944618T3 (da) Nye N-benzensulfonyl-L-prolin-derivater, fremgangsmåde til deres fremstilling og deres anvendelse til terapeutiske formål
HUT76276A (en) 3-substituted 1-arylindole compounds, pharmaceutical compositions containing them and their use
TR199801774T2 (xx) 4-fenil-3, 6-dihidro-2H- piridil t�revlerinin, NMDA resept�r alttip blokerleri olarak kullan�m�.
ATE250413T1 (de) 2-aminotetraline zur behandlung von glaukom
ES8203828A1 (es) Procedimiento para la obtencion de bis (fenoxiacetatos sus- tituidos)de n-alcohil-dialcanolaminas